ArticlePloS one2018
Establishment of patient-derived tumor spheroids for non-small cell lung cancer.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Applications of lung cancer organoids in precision medicine: from bench to bedside.Cell communication and signaling : CCS · 2023Pooled it
- Advantages and research progress of three-dimensional culture systems for lung cancer drug screening (Review).Oncology letters · 2026Review
- Next-Generation In Vitro Pulmonary Platforms for Respiratory Disease Modelling and Therapeutic Development: Current Advances and Future Prospects.Medicina (Kaunas, Lithuania) · 2026Review
- The application of experimental models for the drug discovery for digestive tumors.Molecular cancer · 2026Review
- Research Advances and Disease Modeling in Respiratory Organoids.Biomedicines · 2026Review
- Organoid for Air Pollution Toxicity Assessment: Advances and Environmental Applicability.Environment & health (Washington, D.C.) · 2025Review
- Free-floating patient-derived organotypic tumor spheroids (PDOTS) from non-small cell lung cancer (NSCLC) tumors: a versatile tool for personalized testing of chemotherapeutic drugs.Research in pharmaceutical sciences · 2025Article
- Distal lung organoids derived from adult stem cells as novel tools in deciphering mechanisms of lung regeneration, infection, and cancer.Stem cells translational medicine · 2025Review
- A novel approach to engineering three-dimensional bladder tumor models for drug testing.Scientific reports · 2024Article
- Drug repurposing for cancer therapy.Signal transduction and targeted therapy · 2024Review
- Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy.Respiratory research · 2024Article
- In vitro modelling of bacterial pneumonia: a comparative analysis of widely applied complex cell culture models.FEMS microbiology reviews · 2024Review
- Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine.Molecular biomedicine · 2024Review
- Comparison of Surgical and Colonoscopy Tissue to Establish Colorectal Patient-derived Organoids.Current cancer drug targets · 2024Article
- Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma.Molecular oncology · 2024Article
- Progress and application of lung-on-a-chip for lung cancer.Frontiers in bioengineering and biotechnology · 2024Review
- Patient-Derived Lung Cancer "Sandwich Cultures" with a Preserved Tumor Microenvironment.Tissue engineering. Part C, Methods · 2024Article
- Alveolar Type 2 Epithelial Cell Organoids: Focus on Culture Methods.Biomedicines · 2023Review
- Microfluidics and Organoids, the Power Couple of Developmental Biology and Oncology Studies.International journal of molecular sciences · 2023Review
- Uncovering the cytotoxic effects of air pollution with multi-modal imaging ofRoyal Society open science · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis of advanced non-small cell lung cancer (NSCLC) patients is poor. One of the reasons for this hampered progress has been a lack of in vitro models that would faithfully recapitulate the heterogeneity of tumors and response to treatment. In this study, surgically resected tumors were obtained from patients with stage I/II NSCLC during curative-intent surgery. Using a 3D patient-derived tumor spheroids culture system, our results demonstrate successful long-term expansion of primary NSCLC cells in vitro (> 120 days). Patient-derived tumor spheroid (PDS) cultures could be established with a success rate of 100% (3 out of 3 samples). Consistent with their growth in culture and their cancer type, many cells within the tumor spheroids were stained positive for Ki67 and thyroid transcription factor-1. The result of this study supports the establishment of an expandable 3D in vitro NSCLC model for drug screening, and enables the potential long term studies such as the establishment of drug resistant models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.